■在考虑已知的危险因素时,尚不清楚使用大麻是否与COVID-19患者的不良健康结局有关,包括烟草的使用。
■在其他已知风险因素的背景下,检查大麻和烟草使用是否与COVID-19的不良健康结果相关。
■这项回顾性队列研究使用了2020年2月1日至2022年1月31日的电子健康记录数据。这项研究包括在美国中西部一家大型学术医疗中心至少1次就诊期间被确定患有COVID-19的患者。
■当前使用大麻和吸烟,正如医疗遭遇中记录的那样。
■住院的健康结果,重症监护病房(ICU)入院,和COVID-19感染后的全因死亡率。使用多变量模型评估了物质使用(大麻和烟草)与这些COVID-19结果之间的关联。
■共纳入72501例COVID-19患者(平均[SD]年龄,48.9[19.3]年;43315[59.7%]女性;9710[13.4%]目前吸烟;17654[24.4%]曾经吸烟;7060[9.7%]目前使用大麻)。目前吸烟与住院风险增加显著相关(比值比[OR],1.72;95%CI,1.62-1.82;P<.001),ICU入院(或,1.22;95%CI,1.10-1.34;P<.001),和全因死亡率(OR,1.37,95%CI,1.20-1.57;P<.001)调整其他因素后。大麻使用与住院风险增加显著相关(OR,1.80;95%CI,1.68-1.93;P<.001)和ICU入院(OR,1.27;95%CI,1.14-1.41;P<.001),但不包括全因死亡率(OR,0.97;95%CI,0.82-1.14,P=0.69)调整吸烟后,疫苗接种,合并症,诊断日期,和人口因素。
这项队列研究的结果表明,使用大麻可能是COVID-19相关并发症的独立危险因素,即使在考虑吸烟之后,疫苗接种状况,合并症,和其他风险因素。
UNASSIGNED: It is unclear whether cannabis use is associated with adverse health outcomes in patients with COVID-19 when accounting for known risk factors, including tobacco use.
UNASSIGNED: To examine whether cannabis and tobacco use are associated with adverse health outcomes from COVID-19 in the context of other known risk factors.
UNASSIGNED: This retrospective cohort study used electronic health record data from February 1, 2020, to January 31, 2022. This study included patients who were identified as having COVID-19 during at least 1 medical visit at a large academic medical center in the Midwest US.
UNASSIGNED: Current cannabis use and tobacco smoking, as documented in the medical encounter.
UNASSIGNED: Health outcomes of hospitalization, intensive care unit (ICU) admission, and all-cause mortality following COVID-19 infection. The association between substance use (cannabis and tobacco) and these COVID-19 outcomes was assessed using multivariable modeling.
UNASSIGNED: A total of 72 501 patients with COVID-19 were included (mean [SD] age, 48.9 [19.3] years; 43 315 [59.7%] female; 9710 [13.4%] had current smoking; 17 654 [24.4%] had former smoking; and 7060 [9.7%] had current use of cannabis). Current tobacco smoking was significantly associated with increased risk of hospitalization (odds ratio [OR], 1.72; 95% CI, 1.62-1.82; P < .001), ICU admission (OR, 1.22; 95% CI, 1.10-1.34; P < .001), and all-cause mortality (OR, 1.37, 95% CI, 1.20-1.57; P < .001) after adjusting for other factors. Cannabis use was significantly associated with increased risk of hospitalization (OR, 1.80; 95% CI, 1.68-1.93; P < .001) and ICU admission (OR, 1.27; 95% CI, 1.14-1.41; P < .001) but not with all-cause mortality (OR, 0.97; 95% CI, 0.82-1.14, P = .69) after adjusting for tobacco smoking, vaccination, comorbidity, diagnosis date, and demographic factors.
UNASSIGNED: The findings of this cohort study suggest that cannabis use may be an independent risk factor for COVID-19-related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors.